Global Hodgkin Lymphoma Treatment

Hodgkin Lymphoma Treatment Comprehensive Study by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), Application (Hospital, Clinic, Research Center), Treatment (Immunotherapy, Radiation therapy, Chemotherapy, Others), Route of Drug Administration (Oral, Injection, Intravenously) Players and Region - Global Market Outlook to 2030

Hodgkin Lymphoma Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hodgkin Lymphoma Treatment
According to the American Society, there were 8,110 new cases and 1,000 deaths in 2019 for Hodgkin Lymphoma. Such Increase in number of new cases diagnosed every year has been driving the Hodgkin’s lymphoma treatment market. Further, Lymphomas are cancers that start in white blood cells called lymphocytes. Two main types are Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. Lymphoma is more commonly observed in patients with HIV. The presence of HIV in patients with Hodgkin's lymphoma can have a negative impact on treatment tolerance and prognosis. Family History has been Linked with a Higher Risk of Hodgkin lymphoma. Symptoms include swollen lymph nodes, especially in the part of the body where the lymphoma starts to grow. Other symptoms include fever, night sweats, feeling tired, and weight loss.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is fragmented with numerous player who are involved in discovering new drug treatment for Hodgkin Lymphoma. For Instance, March 2017, KEYTRUDA is approved for use in adult patients at a fixed dose of 200 mg and in pediatric patients at a dose of 2 mg/kg (up to a maximum of 200 mg). It is administered intravenously every three weeks until disease progression or unacceptable toxicity, or up to 24 months in patients without disease progression. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hodgkin Lymphoma Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Cell Medica Limited (United Kingdom), Cellular Biomedicine Group, Inc.(United States), Constellation Pharmaceuticals, Inc.(United States), Curis, Inc.(United States), Faron Pharmaceuticals Oy (Finland), Fate Therapeutics, Inc. (United States), Gamida Cell Ltd. (Israel), Gilead Sciences, Inc. (United States), Incyte Corporation (United States), Merck & Co., Inc. (United States), Mirati Therapeutics Inc. (United States) and Molecular Templates Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are 4sc Ag (Germany), Aeterna Zentaris Inc.(United States), Novartis AG (Switzerland), Actinium Pharmaceuticals (United States) and Hospira Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Hodgkin Lymphoma Treatment market by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501 and Others), Application (Hospital, Clinic and Research Center) and Region.



On the basis of geography, the market of Hodgkin Lymphoma Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Treatment, the sub-segment i.e. Immunotherapy will boost the Hodgkin Lymphoma Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Drug Administration, the sub-segment i.e. Oral will boost the Hodgkin Lymphoma Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
High Unmet Need for a Strong Pipeline of Disease-Modifying Drugs and The Launch of New Therapies for Relapsed or Refractory (R/R) Hodgkin’s Lymphoma

Market Growth Drivers:
Development of Novel Pipeline Drugs, Increased Prevalence of Hodgkin Lymphoma Disease, The rise in the Mortality Rate of Hodgkin lymphoma and Well Established Health Care Facilities

Challenges:
Treatment of Patients with Hodgkin's Lymphoma with Conjoint Conditions, Such as Cardiac Diseases, HIV Infection, and Pregnancy

Restraints:
High-Cost Therapy for the Treatment and Adverse Long-term Side Effects

Opportunities:
Increasing R & D activities for the Treatment of Hodgkin Lymphoma

Market Leaders and their expansionary development strategies
In December 2022, Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved Lunsumio® (mosunetuzumab-axgb) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.
In October 2023, Takeda announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma, and has been previously approved as a therapy for adult patients in Europe in six distinct indications, including those with previously untreated CD30+ Stage IV Hodgkin lymphoma.
October 2017, the Food and Drug Administration approved the second gene altering therapy Yescarta for cancer. The therapy was approved for blood cancer and non-Hodgkin’s lymphoma.

Key Target Audience
Hodgkin Lymphoma Treatment Manufacturers, Hodgkin Lymphoma Treatment Distributors/Traders/Wholesalers, Hodgkin Lymphoma Treatment Subcomponent Manufacturers, Industry Association and Downstream Vendors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Alocrest
  • ANK Program
  • Azacitidine
  • BMS-986016
  • BPX-501
  • Others
By Application
  • Hospital
  • Clinic
  • Research Center
By Treatment
  • Immunotherapy
  • Radiation therapy
  • Chemotherapy
  • Others

By Route of Drug Administration
  • Oral
  • Injection
  • Intravenously

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Development of Novel Pipeline Drugs
      • 3.2.2. Increased Prevalence of Hodgkin Lymphoma Disease
      • 3.2.3. The rise in the Mortality Rate of Hodgkin lymphoma
      • 3.2.4. Well Established Health Care Facilities
    • 3.3. Market Challenges
      • 3.3.1. Treatment of Patients with Hodgkin's Lymphoma with Conjoint Conditions, Such as Cardiac Diseases, HIV Infection, and Pregnancy
    • 3.4. Market Trends
      • 3.4.1. High Unmet Need for a Strong Pipeline of Disease-Modifying Drugs
      • 3.4.2. The Launch of New Therapies for Relapsed or Refractory (R/R) Hodgkin’s Lymphoma
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hodgkin Lymphoma Treatment, by Type, Application, Treatment, Route of Drug Administration and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hodgkin Lymphoma Treatment (Value)
      • 5.2.1. Global Hodgkin Lymphoma Treatment by: Type (Value)
        • 5.2.1.1. Alocrest
        • 5.2.1.2. ANK Program
        • 5.2.1.3. Azacitidine
        • 5.2.1.4. BMS-986016
        • 5.2.1.5. BPX-501
        • 5.2.1.6. Others
      • 5.2.2. Global Hodgkin Lymphoma Treatment by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Research Center
      • 5.2.3. Global Hodgkin Lymphoma Treatment by: Treatment (Value)
        • 5.2.3.1. Immunotherapy
        • 5.2.3.2. Radiation therapy
        • 5.2.3.3. Chemotherapy
        • 5.2.3.4. Others
      • 5.2.4. Global Hodgkin Lymphoma Treatment by: Route of Drug Administration (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Injection
        • 5.2.4.3. Intravenously
      • 5.2.5. Global Hodgkin Lymphoma Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hodgkin Lymphoma Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Cell Medica Limited (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cellular Biomedicine Group, Inc.(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Constellation Pharmaceuticals, Inc.(United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Curis, Inc.(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Faron Pharmaceuticals Oy (Finland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fate Therapeutics, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Gamida Cell Ltd. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Gilead Sciences, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Incyte Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck & Co., Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Mirati Therapeutics Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Molecular Templates Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Hodgkin Lymphoma Treatment Sale, by Type, Application, Treatment, Route of Drug Administration and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hodgkin Lymphoma Treatment (Value)
      • 7.2.1. Global Hodgkin Lymphoma Treatment by: Type (Value)
        • 7.2.1.1. Alocrest
        • 7.2.1.2. ANK Program
        • 7.2.1.3. Azacitidine
        • 7.2.1.4. BMS-986016
        • 7.2.1.5. BPX-501
        • 7.2.1.6. Others
      • 7.2.2. Global Hodgkin Lymphoma Treatment by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Research Center
      • 7.2.3. Global Hodgkin Lymphoma Treatment by: Treatment (Value)
        • 7.2.3.1. Immunotherapy
        • 7.2.3.2. Radiation therapy
        • 7.2.3.3. Chemotherapy
        • 7.2.3.4. Others
      • 7.2.4. Global Hodgkin Lymphoma Treatment by: Route of Drug Administration (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Injection
        • 7.2.4.3. Intravenously
      • 7.2.5. Global Hodgkin Lymphoma Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hodgkin Lymphoma Treatment: by Type(USD Million)
  • Table 2. Hodgkin Lymphoma Treatment Alocrest , by Region USD Million (2018-2023)
  • Table 3. Hodgkin Lymphoma Treatment ANK Program , by Region USD Million (2018-2023)
  • Table 4. Hodgkin Lymphoma Treatment Azacitidine , by Region USD Million (2018-2023)
  • Table 5. Hodgkin Lymphoma Treatment BMS-986016 , by Region USD Million (2018-2023)
  • Table 6. Hodgkin Lymphoma Treatment BPX-501 , by Region USD Million (2018-2023)
  • Table 7. Hodgkin Lymphoma Treatment Others , by Region USD Million (2018-2023)
  • Table 8. Hodgkin Lymphoma Treatment: by Application(USD Million)
  • Table 9. Hodgkin Lymphoma Treatment Hospital , by Region USD Million (2018-2023)
  • Table 10. Hodgkin Lymphoma Treatment Clinic , by Region USD Million (2018-2023)
  • Table 11. Hodgkin Lymphoma Treatment Research Center , by Region USD Million (2018-2023)
  • Table 12. Hodgkin Lymphoma Treatment: by Treatment(USD Million)
  • Table 13. Hodgkin Lymphoma Treatment Immunotherapy , by Region USD Million (2018-2023)
  • Table 14. Hodgkin Lymphoma Treatment Radiation therapy , by Region USD Million (2018-2023)
  • Table 15. Hodgkin Lymphoma Treatment Chemotherapy , by Region USD Million (2018-2023)
  • Table 16. Hodgkin Lymphoma Treatment Others , by Region USD Million (2018-2023)
  • Table 17. Hodgkin Lymphoma Treatment: by Route of Drug Administration(USD Million)
  • Table 18. Hodgkin Lymphoma Treatment Oral , by Region USD Million (2018-2023)
  • Table 19. Hodgkin Lymphoma Treatment Injection , by Region USD Million (2018-2023)
  • Table 20. Hodgkin Lymphoma Treatment Intravenously , by Region USD Million (2018-2023)
  • Table 21. South America Hodgkin Lymphoma Treatment, by Country USD Million (2018-2023)
  • Table 22. South America Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 23. South America Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 24. South America Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 25. South America Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 26. Brazil Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 27. Brazil Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 28. Brazil Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 29. Brazil Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 30. Argentina Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 31. Argentina Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 32. Argentina Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 33. Argentina Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 34. Rest of South America Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 35. Rest of South America Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 36. Rest of South America Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 37. Rest of South America Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 38. Asia Pacific Hodgkin Lymphoma Treatment, by Country USD Million (2018-2023)
  • Table 39. Asia Pacific Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 40. Asia Pacific Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 41. Asia Pacific Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 42. Asia Pacific Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 43. China Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 44. China Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 45. China Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 46. China Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 47. Japan Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 48. Japan Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 49. Japan Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 50. Japan Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 51. India Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 52. India Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 53. India Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 54. India Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 55. South Korea Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 56. South Korea Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 57. South Korea Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 58. South Korea Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 59. Taiwan Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 60. Taiwan Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 61. Taiwan Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 62. Taiwan Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 63. Australia Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 64. Australia Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 65. Australia Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 66. Australia Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 71. Europe Hodgkin Lymphoma Treatment, by Country USD Million (2018-2023)
  • Table 72. Europe Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 73. Europe Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 74. Europe Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 75. Europe Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 76. Germany Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 77. Germany Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 78. Germany Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 79. Germany Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 80. France Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 81. France Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 82. France Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 83. France Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 84. Italy Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 85. Italy Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 86. Italy Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 87. Italy Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 88. United Kingdom Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 89. United Kingdom Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 90. United Kingdom Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 91. United Kingdom Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 92. Netherlands Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 93. Netherlands Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 94. Netherlands Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 95. Netherlands Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 96. Rest of Europe Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 97. Rest of Europe Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 98. Rest of Europe Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 99. Rest of Europe Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 100. MEA Hodgkin Lymphoma Treatment, by Country USD Million (2018-2023)
  • Table 101. MEA Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 102. MEA Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 103. MEA Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 104. MEA Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 105. Middle East Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 106. Middle East Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 107. Middle East Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 108. Middle East Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 109. Africa Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 110. Africa Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 111. Africa Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 112. Africa Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 113. North America Hodgkin Lymphoma Treatment, by Country USD Million (2018-2023)
  • Table 114. North America Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 115. North America Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 116. North America Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 117. North America Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 118. United States Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 119. United States Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 120. United States Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 121. United States Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 122. Canada Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 123. Canada Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 124. Canada Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 125. Canada Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 126. Mexico Hodgkin Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 127. Mexico Hodgkin Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 128. Mexico Hodgkin Lymphoma Treatment, by Treatment USD Million (2018-2023)
  • Table 129. Mexico Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2018-2023)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Hodgkin Lymphoma Treatment: by Type(USD Million)
  • Table 143. Hodgkin Lymphoma Treatment Alocrest , by Region USD Million (2025-2030)
  • Table 144. Hodgkin Lymphoma Treatment ANK Program , by Region USD Million (2025-2030)
  • Table 145. Hodgkin Lymphoma Treatment Azacitidine , by Region USD Million (2025-2030)
  • Table 146. Hodgkin Lymphoma Treatment BMS-986016 , by Region USD Million (2025-2030)
  • Table 147. Hodgkin Lymphoma Treatment BPX-501 , by Region USD Million (2025-2030)
  • Table 148. Hodgkin Lymphoma Treatment Others , by Region USD Million (2025-2030)
  • Table 149. Hodgkin Lymphoma Treatment: by Application(USD Million)
  • Table 150. Hodgkin Lymphoma Treatment Hospital , by Region USD Million (2025-2030)
  • Table 151. Hodgkin Lymphoma Treatment Clinic , by Region USD Million (2025-2030)
  • Table 152. Hodgkin Lymphoma Treatment Research Center , by Region USD Million (2025-2030)
  • Table 153. Hodgkin Lymphoma Treatment: by Treatment(USD Million)
  • Table 154. Hodgkin Lymphoma Treatment Immunotherapy , by Region USD Million (2025-2030)
  • Table 155. Hodgkin Lymphoma Treatment Radiation therapy , by Region USD Million (2025-2030)
  • Table 156. Hodgkin Lymphoma Treatment Chemotherapy , by Region USD Million (2025-2030)
  • Table 157. Hodgkin Lymphoma Treatment Others , by Region USD Million (2025-2030)
  • Table 158. Hodgkin Lymphoma Treatment: by Route of Drug Administration(USD Million)
  • Table 159. Hodgkin Lymphoma Treatment Oral , by Region USD Million (2025-2030)
  • Table 160. Hodgkin Lymphoma Treatment Injection , by Region USD Million (2025-2030)
  • Table 161. Hodgkin Lymphoma Treatment Intravenously , by Region USD Million (2025-2030)
  • Table 162. South America Hodgkin Lymphoma Treatment, by Country USD Million (2025-2030)
  • Table 163. South America Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 164. South America Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 165. South America Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 166. South America Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 167. Brazil Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 168. Brazil Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 169. Brazil Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 170. Brazil Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 171. Argentina Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 172. Argentina Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 173. Argentina Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 174. Argentina Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 175. Rest of South America Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 176. Rest of South America Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 177. Rest of South America Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 178. Rest of South America Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 179. Asia Pacific Hodgkin Lymphoma Treatment, by Country USD Million (2025-2030)
  • Table 180. Asia Pacific Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 181. Asia Pacific Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 182. Asia Pacific Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 183. Asia Pacific Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 184. China Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 185. China Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 186. China Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 187. China Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 188. Japan Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 189. Japan Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 190. Japan Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 191. Japan Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 192. India Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 193. India Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 194. India Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 195. India Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 196. South Korea Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 197. South Korea Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 198. South Korea Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 199. South Korea Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 200. Taiwan Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 201. Taiwan Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 202. Taiwan Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 203. Taiwan Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 204. Australia Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 205. Australia Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 206. Australia Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 207. Australia Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 209. Rest of Asia-Pacific Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 212. Europe Hodgkin Lymphoma Treatment, by Country USD Million (2025-2030)
  • Table 213. Europe Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 214. Europe Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 215. Europe Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 216. Europe Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 217. Germany Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 218. Germany Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 219. Germany Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 220. Germany Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 221. France Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 222. France Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 223. France Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 224. France Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 225. Italy Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 226. Italy Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 227. Italy Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 228. Italy Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 229. United Kingdom Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 230. United Kingdom Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 231. United Kingdom Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 232. United Kingdom Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 233. Netherlands Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 234. Netherlands Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 235. Netherlands Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 236. Netherlands Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 237. Rest of Europe Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 238. Rest of Europe Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 239. Rest of Europe Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 240. Rest of Europe Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 241. MEA Hodgkin Lymphoma Treatment, by Country USD Million (2025-2030)
  • Table 242. MEA Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 243. MEA Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 244. MEA Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 245. MEA Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 246. Middle East Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 247. Middle East Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 248. Middle East Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 249. Middle East Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 250. Africa Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 251. Africa Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 252. Africa Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 253. Africa Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 254. North America Hodgkin Lymphoma Treatment, by Country USD Million (2025-2030)
  • Table 255. North America Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 256. North America Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 257. North America Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 258. North America Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 259. United States Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 260. United States Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 261. United States Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 262. United States Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 263. Canada Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 264. Canada Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 265. Canada Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 266. Canada Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 267. Mexico Hodgkin Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 268. Mexico Hodgkin Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 269. Mexico Hodgkin Lymphoma Treatment, by Treatment USD Million (2025-2030)
  • Table 270. Mexico Hodgkin Lymphoma Treatment, by Route of Drug Administration USD Million (2025-2030)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hodgkin Lymphoma Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Hodgkin Lymphoma Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Hodgkin Lymphoma Treatment: by Treatment USD Million (2018-2023)
  • Figure 7. Global Hodgkin Lymphoma Treatment: by Route of Drug Administration USD Million (2018-2023)
  • Figure 8. South America Hodgkin Lymphoma Treatment Share (%), by Country
  • Figure 9. Asia Pacific Hodgkin Lymphoma Treatment Share (%), by Country
  • Figure 10. Europe Hodgkin Lymphoma Treatment Share (%), by Country
  • Figure 11. MEA Hodgkin Lymphoma Treatment Share (%), by Country
  • Figure 12. North America Hodgkin Lymphoma Treatment Share (%), by Country
  • Figure 13. Global Hodgkin Lymphoma Treatment share by Players 2023 (%)
  • Figure 14. Global Hodgkin Lymphoma Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Hodgkin Lymphoma Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Cell Medica Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Cell Medica Limited (United Kingdom) Revenue: by Geography 2023
  • Figure 19. Cellular Biomedicine Group, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 20. Cellular Biomedicine Group, Inc.(United States) Revenue: by Geography 2023
  • Figure 21. Constellation Pharmaceuticals, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 22. Constellation Pharmaceuticals, Inc.(United States) Revenue: by Geography 2023
  • Figure 23. Curis, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 24. Curis, Inc.(United States) Revenue: by Geography 2023
  • Figure 25. Faron Pharmaceuticals Oy (Finland) Revenue, Net Income and Gross profit
  • Figure 26. Faron Pharmaceuticals Oy (Finland) Revenue: by Geography 2023
  • Figure 27. Fate Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Fate Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Gamida Cell Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Gamida Cell Ltd. (Israel) Revenue: by Geography 2023
  • Figure 31. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Gilead Sciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Incyte Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 34. Incyte Corporation (United States) Revenue: by Geography 2023
  • Figure 35. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Mirati Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Mirati Therapeutics Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Molecular Templates Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Molecular Templates Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Global Hodgkin Lymphoma Treatment: by Type USD Million (2025-2030)
  • Figure 42. Global Hodgkin Lymphoma Treatment: by Application USD Million (2025-2030)
  • Figure 43. Global Hodgkin Lymphoma Treatment: by Treatment USD Million (2025-2030)
  • Figure 44. Global Hodgkin Lymphoma Treatment: by Route of Drug Administration USD Million (2025-2030)
  • Figure 45. South America Hodgkin Lymphoma Treatment Share (%), by Country
  • Figure 46. Asia Pacific Hodgkin Lymphoma Treatment Share (%), by Country
  • Figure 47. Europe Hodgkin Lymphoma Treatment Share (%), by Country
  • Figure 48. MEA Hodgkin Lymphoma Treatment Share (%), by Country
  • Figure 49. North America Hodgkin Lymphoma Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Cell Medica Limited (United Kingdom)
  • Cellular Biomedicine Group, Inc.(United States)
  • Constellation Pharmaceuticals, Inc.(United States)
  • Curis, Inc.(United States)
  • Faron Pharmaceuticals Oy (Finland)
  • Fate Therapeutics, Inc. (United States)
  • Gamida Cell Ltd. (Israel)
  • Gilead Sciences, Inc. (United States)
  • Incyte Corporation (United States)
  • Merck & Co., Inc. (United States)
  • Mirati Therapeutics Inc. (United States)
  • Molecular Templates Inc. (United States)
Additional players considered in the study are as follows:
4sc Ag (Germany) , Aeterna Zentaris Inc.(United States) , Novartis AG (Switzerland) , Actinium Pharmaceuticals (United States) , Hospira Inc. (United States) ,
Select User Access Type

Key Highlights of Report


Mar 2024 249 Pages 57 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hodgkin Lymphoma Treatment Quantitative research analysis
Global Hodgkin Lymphoma Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Cell Medica Limited (United Kingdom), Cellular Biomedicine Group, Inc.(United States), Constellation Pharmaceuticals, Inc.(United States), Curis, Inc.(United States), Faron Pharmaceuticals Oy (Finland), Fate Therapeutics, Inc. (United States), Gamida Cell Ltd. (Israel), Gilead Sciences, Inc. (United States), Incyte Corporation (United States), Merck & Co., Inc. (United States), Mirati Therapeutics Inc. (United States) and Molecular Templates Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"High Unmet Need for a Strong Pipeline of Disease-Modifying Drugs " is seen as one of major influencing trends for Hodgkin Lymphoma Treatment Market during projected period 2023-2030.
The Hodgkin Lymphoma Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hodgkin Lymphoma Treatment Report?

Have a Query? Click Here

Other Related Reports

Cervical Cancer Diagnostic Tests Comprehensive Study by Type (Pap Test, HPV Typing Test, Colposcopy, Biopsy, Bimanual Pelvic Examination), Application (Hospitals, Specialty Clinics, Cancer and Radiat...
$ 3450
Overactive Bladder Treatment Comprehensive Study by Type (Self-Care (Absorbent Pads, Scheduled Toileting, Double Voiding, Bladder Training), Therapies (Biofeedback, Kegel Exercise), Medications (Blad...
$ 3750
Ankylosing Spondylitis Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgical Centers), Route of Administration (Oral, Parenteral), Treatment Type (Nonsteroidal Anti-Inflammatory...
$ 3750
Infantile Spasms Therapeutics Comprehensive Study by Type (Monotherapy, Combination Therapy), Drug Form (Solid, Liquid), End Users (Infants, Children < 2 Years), Route of Administration (Oral, Parent...
$ 3500
Dry Eye Disease Comprehensive Study by Type (Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogue), Application (Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Ph...
$ 3450
Hypercalcemia Treatment Comprehensive Study by Application (Mild Hypercalcemia, Moderate Hypercalcemia, Severe Hypercalcemia), Treatment (Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidro...
$ 3650